Thalamic Atrophy Without Whole Brain Atrophy Is Associated With Absence of 2-Year NEDA in Multiple Sclerosis

Overview

Journal Front Neurol

Specialty Neurology

Date 2019 May 28

PMID 31130911

Citations 16

Authors

Katariina Hanninen

Matias Viitala

Teemu Paavilainen

Jari O Karhu

Juha Rinne

Juha Koikkalainen

Jyrki Lotjonen

Merja Soilu-Hanninen

Affiliations

Soon will be listed here.

Abstract

To study which brain volume measures best differentiate early relapsing MS (RMS) and secondary progressive MS (SPMS) patients and correlate with disability and cognition. To test whether isolated thalamic atrophy at study baseline correlates with NEDA (no evidence of disease activity) at 2 years. Total and regional brain volumes were measured from 24 newly diagnosed RMS patients 6 months after initiation of therapy and 2 years thereafter, and in 36 SPMS patients. Volumes were measured by SIENAX and cNeuro. The patients were divided into subgroups based on whole brain parenchyma (BP) and thalamic atrophy at baseline. Standard scores (-scores) were computed by comparing individual brain volumes against healthy controls. A -score cut-off of -1.96 was applied to separate atrophic from normal brain volumes. The Expanded Disability Status Scale (EDSS) and Symbol Digit Modalities Test (SDMT) were assessed at baseline and at 2 years. Differences in achieving NEDA-3, NEDA-4, EDSS progression, and SDMT change were analyzed between patients with no thalamic or BP atrophy and in patients with isolated thalamic atrophy at baseline. At baseline, 7 SPMS and 12 RMS patients had no brain atrophy, 8 SPMS and 10 RMS patients had isolated thalamic atrophy and 2 RMS and 20 SPMS patients had both BP and thalamic atrophy. NEDA-3 was reached in 11/19 patients with no brain atrophy but only in 2/16 patients with isolated thalamic atrophy ( = 0.012). NEDA-4 was reached in 7/19 patients with no brain atrophy and in 1/16 of the patients with isolated thalamic atrophy ( = 0.047). At 2 years, EDSS was same or better in 16/19 patients with no brain atrophy but only in 5/17 patients with isolated thalamic atrophy ( = 0.002). There was no significant difference in the EDSS, relapses or SDMT between patients with isolated thalamic atrophy and no atrophy at baseline. Patients with isolated thalamic atrophy were at a higher risk for not reaching 2-year NEDA-3 and for EDSS increase than patients with no identified brain atrophy. The groups were clinically indistinguishable. A single measurement of thalamic and whole brain atrophy could help identify patients needing most effective therapies from early on.

Citing Articles

Patients with relapsing-remitting multiple sclerosis show accelerated whole brain volume and thalamic volume loss early in disease.

Opfer R, Schwab M, Bangoura S, Biswas M, Kruger J, Spies L Neuroradiology. 2024; 67(1):99-107.

PMID: 39607558 DOI: 10.1007/s00234-024-03516-7.

Assessing disease progression and treatment response in progressive multiple sclerosis.

Comi G, Dalla Costa G, Stankoff B, Hartung H, Soelberg Sorensen P, Vermersch P Nat Rev Neurol. 2024; 20(10):573-586.

PMID: 39251843 DOI: 10.1038/s41582-024-01006-1.

Automated magnetic resonance imaging quantification of cerebral parenchymal and ventricular volume following subarachnoid hemorrhage: associations with cognition.

Jorna L, Khosdelazad S, Klos J, Rakers S, van der Hoorn A, Potze J Brain Imaging Behav. 2024; 18(2):421-429.

PMID: 38294581 PMC: 10830824. DOI: 10.1007/s11682-024-00855-0.

Neurodegeneration and its potential markers in the diagnosing of secondary progressive multiple sclerosis. A review.

Pogoda-Wesolowska A, Dziedzic A, Maciak K, Stpien A, Dziaduch M, Saluk J Front Mol Neurosci. 2023; 16:1210091.

PMID: 37781097 PMC: 10535108. DOI: 10.3389/fnmol.2023.1210091.

Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis.

Maier S, Barcutean L, Andone S, Manu D, Sarmasan E, Bajko Z Int J Mol Sci. 2023; 24(5).

PMID: 36901807 PMC: 10002756. DOI: 10.3390/ijms24054375.

References

Smith S, Zhang Y, Jenkinson M, Chen J, Matthews P, Federico A . Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage. 2002; 17(1):479-89. DOI: 10.1006/nimg.2002.1040. View

Smith S, Jenkinson M, Woolrich M, Beckmann C, Behrens T, Johansen-Berg H . Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage. 2004; 23 Suppl 1:S208-19. DOI: 10.1016/j.neuroimage.2004.07.051. View

Enzinger C, Fazekas F, Matthews P, Ropele S, Schmidt H, Smith S . Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. Neurology. 2005; 64(10):1704-11. DOI: 10.1212/01.WNL.0000161871.83614.BB. View

Marcus D, Wang T, Parker J, Csernansky J, Morris J, Buckner R . Open Access Series of Imaging Studies (OASIS): cross-sectional MRI data in young, middle aged, nondemented, and demented older adults. J Cogn Neurosci. 2007; 19(9):1498-507. DOI: 10.1162/jocn.2007.19.9.1498. View

Fisher E, Lee J, Nakamura K, Rudick R . Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol. 2008; 64(3):255-65. DOI: 10.1002/ana.21436. View

Lotjonen J, Wolz R, Koikkalainen J, Thurfjell L, Waldemar G, Soininen H . Fast and robust multi-atlas segmentation of brain magnetic resonance images. Neuroimage. 2009; 49(3):2352-65. DOI: 10.1016/j.neuroimage.2009.10.026. View

Rocca M, Mesaros S, Pagani E, Sormani M, Comi G, Filippi M . Thalamic damage and long-term progression of disability in multiple sclerosis. Radiology. 2010; 257(2):463-9. DOI: 10.1148/radiol.10100326. View

Patenaude B, Smith S, Kennedy D, Jenkinson M . A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage. 2011; 56(3):907-22. PMC: 3417233. DOI: 10.1016/j.neuroimage.2011.02.046. View

Roosendaal S, Bendfeldt K, Vrenken H, Polman C, Borgwardt S, Radue E . Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler. 2011; 17(9):1098-106. DOI: 10.1177/1352458511404916. View

10.

Battaglini M, Jenkinson M, De Stefano N . Evaluating and reducing the impact of white matter lesions on brain volume measurements. Hum Brain Mapp. 2011; 33(9):2062-71. PMC: 6870255. DOI: 10.1002/hbm.21344. View

11.

Wang Y, Catindig J, Hilal S, Soon H, Ting E, Wong T . Multi-stage segmentation of white matter hyperintensity, cortical and lacunar infarcts. Neuroimage. 2012; 60(4):2379-88. DOI: 10.1016/j.neuroimage.2012.02.034. View

12.

Popescu V, Battaglini M, Hoogstrate W, Verfaillie S, Sluimer I, van Schijndel R . Optimizing parameter choice for FSL-Brain Extraction Tool (BET) on 3D T1 images in multiple sclerosis. Neuroimage. 2012; 61(4):1484-94. DOI: 10.1016/j.neuroimage.2012.03.074. View

13.

Bergsland N, Horakova D, Dwyer M, Dolezal O, Seidl Z, Vaneckova M . Subcortical and cortical gray matter atrophy in a large sample of patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol. 2012; 33(8):1573-8. PMC: 7966546. DOI: 10.3174/ajnr.A3086. View

14.

Lublin F, Cofield S, Cutter G, Conwit R, Narayana P, Nelson F . Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013; 73(3):327-40. PMC: 3631288. DOI: 10.1002/ana.23863. View

15.

Zivadinov R, Havrdova E, Bergsland N, Tyblova M, Hagemeier J, Seidl Z . Thalamic atrophy is associated with development of clinically definite multiple sclerosis. Radiology. 2013; 268(3):831-41. DOI: 10.1148/radiol.13122424. View

16.

Perez-Miralles F, Sastre-Garriga J, Tintore M, Arrambide G, Nos C, Perkal H . Clinical impact of early brain atrophy in clinically isolated syndromes. Mult Scler. 2013; 19(14):1878-86. DOI: 10.1177/1352458513488231. View

17.

Filippi M, Preziosa P, Copetti M, Riccitelli G, Horsfield M, Martinelli V . Gray matter damage predicts the accumulation of disability 13 years later in MS. Neurology. 2013; 81(20):1759-67. DOI: 10.1212/01.wnl.0000435551.90824.d0. View

18.

De Stefano N, Airas L, Grigoriadis N, Mattle H, ORiordan J, Oreja-Guevara C . Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs. 2014; 28(2):147-56. DOI: 10.1007/s40263-014-0140-z. View

19.

Jacobsen C, Hagemeier J, Myhr K, Nyland H, Lode K, Bergsland N . Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. J Neurol Neurosurg Psychiatry. 2014; 85(10):1109-15. DOI: 10.1136/jnnp-2013-306906. View

20.

Arnold D, Calabresi P, Kieseier B, Sheikh S, Deykin A, Zhu Y . Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis. BMC Neurol. 2015; 14:240. PMC: 4311432. DOI: 10.1186/s12883-014-0240-x. View